Dme Capital Management, LP Gain Therapeutics, Inc. Transaction History
Dme Capital Management, LP
- $2.18 Trillion
- Q1 2024
A detailed history of Dme Capital Management, LP transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Dme Capital Management, LP holds 566,130 shares of GANX stock, worth $724,646. This represents 0.1% of its overall portfolio holdings.
Number of Shares
566,130Holding current value
$724,646% of portfolio
0.1%Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
33Shares Held
2.58MCall Options Held
22.2KPut Options Held
16K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$753,1640.1% of portfolio
-
Raymond James & Associates St Petersburg, FL260KShares$332,8240.0% of portfolio
-
Royal Bank Of Canada Toronto, A6249KShares$318,0800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$226,6760.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$157,4400.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $15.2M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...